Researchers have successfully demonstrated that T cells can be modified in vivo with mRNA technology, bypassing the need for extraction, chemotherapy and re-infusion associated with traditional CAR T therapy.
CAR T-mRNA Therapy For Cardiac Fibrosis: A New Way Forward
